Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 0.59 |
| ▸ | ACHE | P22303 | 3/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7674020 | 1.00 | SLC6A4 (0.59) | SLC6A4ACHECYP2D6SLC22A1CHRM2 | |
| SCHEMBL20698854 | 0.84 | SLC6A4 (0.44) | SLC6A4ACHECYP2D6SLC22A1CHRM2 | |
| SCHEMBL19123555 | 0.82 | SLC6A4 (0.50) | SLC6A4CYP2D6CHRM2OPRM1SLC6A2 | |
| SCHEMBL17119222 | 0.81 | FNTA (0.49) | SLC6A4CYP2D6SLC22A1CHRM2OPRM1 | |
| SCHEMBL7680548 | 0.81 | FNTA (0.49) | SLC6A4CYP2D6SLC22A1CHRM2OPRM1 | |
| SCHEMBL23333048 | 0.81 | ACHE (0.55) | SLC6A4ACHECYP2D6SLC22A1CHRM2 | |
| SCHEMBL13078444 | 0.80 | FNTA (0.49) | SLC6A4ACHECYP2D6SLC22A1CHRM2 | |
| SCHEMBL11226331 | 0.77 | SLC6A4 (0.49) | SLC6A4CYP2D6OPRM1SLC6A2SLC6A3 | |
| SCHEMBL13485648 | 0.75 | OPRM1 (0.41) | SLC6A4ACHECYP2D6SLC22A1CHRM2 | |
| SCHEMBL19146081 | 0.74 | ACHE (0.76) | SLC6A4ACHECYP2D6SLC22A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232270-B2 | Bivalent (−)-meptazinol compounds and/or their salts, and their preparation and futilization | FUDAN UNIVERSITY (CN) | 2012-07-31 | — | — | US | disclosed |
| US-8232270-B2 | Bivalent (−)-meptazinol compounds and/or their salts, and their preparation and futilization | FUDAN UNIVERSITY (CN) | 2012-07-31 | — | — | US | disclosed |
| US-20100035861-A1 | Meptazinol Biligand Derivatives and/or their Salts, Preparation Method and Uses Thereof | FUDAN UNIVERSITY (CN) | 2010-02-11 | — | — | US | disclosed |
| EP-2048134-A1 | MEPTAZINOL BILIGAND DERIVATIVES AND/OR THEIR SALTS, PREPARATION METHOD AND USES THEREOF | Fudan University (CN) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035861-A1 | Meptazinol Biligand Derivatives and/or their Salts, Preparation Method and Uses Thereof | BCHE, ACHE, APEH | SLC6A4 1477/4885ACHE 2/4885CYP2D6 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.